drugset
drugset / Trial / NCT05409924

First-in-human Single and Multiple Dose Trial of ATR-258

NCT05409924 ↗

Phase 1 Completed 71 enrolled Atrogi AB CRS Clinical Research Services Mannheim GmbH · collabKey2Compliance · collab
RandomizedSequentialTriple-blindTreatment

Summary

This is a single-site, randomized, double-blinded, placebo-controlled, First-in-Human trial, conducted in 3 parts.

Timeline

Start
2022-04-11
Primary completion
2023-10-04
Completion
2023-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ATR-258 Unknown — —

Indications

type 2 diabetes mellitus